JPH0380480B2 - - Google Patents
Info
- Publication number
- JPH0380480B2 JPH0380480B2 JP24790483A JP24790483A JPH0380480B2 JP H0380480 B2 JPH0380480 B2 JP H0380480B2 JP 24790483 A JP24790483 A JP 24790483A JP 24790483 A JP24790483 A JP 24790483A JP H0380480 B2 JPH0380480 B2 JP H0380480B2
- Authority
- JP
- Japan
- Prior art keywords
- creatine
- creatinine
- formaldehyde
- reagent
- catalase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 claims description 98
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 claims description 90
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims description 57
- 229940109239 creatinine Drugs 0.000 claims description 49
- 229960003624 creatine Drugs 0.000 claims description 45
- 239000006046 creatine Substances 0.000 claims description 45
- 239000003153 chemical reaction reagent Substances 0.000 claims description 35
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 33
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims description 23
- 102000016938 Catalase Human genes 0.000 claims description 20
- 108010053835 Catalase Proteins 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 20
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 14
- 102000004190 Enzymes Human genes 0.000 claims description 12
- 108090000790 Enzymes Proteins 0.000 claims description 12
- 238000004040 coloring Methods 0.000 claims description 11
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 claims description 10
- 108010060059 Sarcosine Oxidase Proteins 0.000 claims description 9
- 102000008118 Sarcosine oxidase Human genes 0.000 claims description 9
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 claims description 8
- 108010077078 Creatinase Proteins 0.000 claims description 7
- 239000004471 Glycine Substances 0.000 claims description 7
- 108010066906 Creatininase Proteins 0.000 claims description 5
- ZJJADRZINPLZGS-UHFFFAOYSA-N 3-hydrazinyl-1,2,4-triazol-4-amine Chemical compound NNC1=NN=CN1N ZJJADRZINPLZGS-UHFFFAOYSA-N 0.000 claims description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 3
- 101710106660 Shutoff alkaline exonuclease Proteins 0.000 description 14
- 238000006243 chemical reaction Methods 0.000 description 10
- 238000006911 enzymatic reaction Methods 0.000 description 8
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 238000005259 measurement Methods 0.000 description 5
- 239000008363 phosphate buffer Substances 0.000 description 5
- DRBBFCLWYRJSJZ-UHFFFAOYSA-N N-phosphocreatine Chemical compound OC(=O)CN(C)C(=N)NP(O)(O)=O DRBBFCLWYRJSJZ-UHFFFAOYSA-N 0.000 description 4
- 108010077895 Sarcosine Proteins 0.000 description 4
- 238000011088 calibration curve Methods 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 229940043230 sarcosine Drugs 0.000 description 4
- 241000589516 Pseudomonas Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 210000001124 body fluid Anatomy 0.000 description 3
- 239000010839 body fluid Substances 0.000 description 3
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical compound OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- 241000589565 Flavobacterium Species 0.000 description 2
- 208000029578 Muscle disease Diseases 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000012086 standard solution Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 210000005239 tubule Anatomy 0.000 description 2
- 241000588986 Alcaligenes Species 0.000 description 1
- 208000037157 Azotemia Diseases 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- 102000004420 Creatine Kinase Human genes 0.000 description 1
- 108010042126 Creatine kinase Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010018367 Glomerulonephritis chronic Diseases 0.000 description 1
- 206010020850 Hyperthyroidism Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000192041 Micrococcus Species 0.000 description 1
- 206010028289 Muscle atrophy Diseases 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- MMBMIVSDYYPRHH-UHFFFAOYSA-N hydrogen peroxide Chemical compound OO.OO MMBMIVSDYYPRHH-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 230000020763 muscle atrophy Effects 0.000 description 1
- 201000000585 muscular atrophy Diseases 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 208000009852 uremia Diseases 0.000 description 1
- 201000002327 urinary tract obstruction Diseases 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Description
本発明は酵素を用いた体液中特に血清あるいは
尿中のクレアチニン及びクレアチンの同時定量方
法並びにそのキツトに関する。
クレアチンは主として肝で合成されて血中に入
り、その大部分は筋肉に分布し、クレアチン・キ
ナーゼの作用により高エネルギー化合物であるク
レアチン・リン酸に合成されてエネルギー源とし
て重要な役割をはたしている、クレアチンは腎糸
球体から過されるが、尿細管で再吸収されるた
め、成人男子ではほとんど尿中に排泄されない。
血清クレアチン濃度は原発性筋疾患、筋萎縮、甲
状腺機能亢進症などで増加しクレアチン尿をきた
す。一方クレアチンの無水物であるクレアチニン
は筋肉ではクレアチンリン酸から不可逆的かつ非
酵素的に脱水されて生じ、代謝終産物として腎糸
球体を通過し尿細管で再吸収されることなく排泄
される。したがつて尿毒症、慢性腎炎、尿路閉塞
などの腎機能疾患の時には、クレアチニンを正常
に排泄できずに血清中にクレアチニンが増加して
くる。このように血清及び尿中のクレアチン及び
クレアチニン濃度を測定することにより、これら
の疾患の診断の重要な指標となる。その検体数は
年々増加の一途をたどつている。
従来よく用いられているクレアチニン定量法は
アルカリ性下でピクリン酸と反応させて発色する
ヤツフエ反応を用いたものである(Bonsnes and
Taussky,J.Biol.Chem.158 581(1945))。この
方法はクレアチニンに特異的な反応を示さないの
で、体液中の他の物質の影響を受けるため正確な
クレアチニン量を求め得ないし、ピクリン酸が反
応容器や分析機を汚染させ測定誤差の原因とな
る。また自動分析機に適応させた場合には他の測
定項目に影響を与えるなど、取扱い上、問題が多
かつた。
一方クレアチンは酸性で加熱してクレアチニン
に変え、生じたクレアチニンを上記のヤツフエ反
応で測定し酸性加熱前のクレアチニン量との差か
らクレアチニン量を推定する方法である、このた
めクレアチニン定量法は誤差を生じやすく操作が
繁雑な欠点がある。このような従来の欠点を克服
した、操作が簡単で正確なクレアチニン及びクレ
アチンの同時定量方法の開発が望まれていた。
このような実情を背景に迅速で高感度かつ正確
なクレアチニン及びクレアチンの同時定量方法を
確立すべく鋭意研究を重ねた結果、クレアチニ
ン・アミドヒドロラーゼ、クレアチン・アミジノ
ヒドロラーゼ、ザルコシン・オキシダーゼ、カタ
ラーゼの4酵素及び発色試薬を用いると所期の目
的が達成されることを見出し本発明に到達した。
本発明は、試料の1つのアリコートにクレアチニ
ン・アミドヒドロラーゼ、クレアチン・アミジノ
ヒドロラーゼ、ザルコシン・オキシダーゼの3酵
素を組合せて作用させて該試料中のクレアチンと
クレアチニンをホルムアルデヒド、過酸化水素及
びグリシンに変換し、上記試料の他のアリコート
にクレアチン・アミジノヒドロラーゼとザルコシ
ン・オキシダーゼの2酵素を組合せて作用させて
試料中のクレアチンをホルムアルデヒド、過酸化
水素及びグリシンに変換し、各々の場合に生じた
過酸化水素をカタラーゼの存在下にメタノールと
反応させてホルムアルデヒドに変換させることに
よりクレアチニン及びクレアチン各1分子当り2
分子のホルムアルデヒドを生成させ、各々生じた
ホルムアルデヒドに発色試薬を作用させ、生じた
発色体を測定して各々クレアチニンとクレアチン
の合計量及びクレアチンの量を定量し、該合計量
からクレアチンの量を差引くことによりクレアチ
ニンの量を算出することからなるクレアチニンと
クレアチンの同時定量方法である。本発明によれ
ば試料にクレアチニン・アミドヒドロラーゼ
〔EC3.5.2.10;以後CRNと略す〕、クレアチン・ア
ミジノヒドロラーゼ〔EC3.5.3.3;以後CRと略
す〕、ザルコシン・オキシダーゼ〔EC1.5.3.1;以
後SOXと略す〕の3酵素を組み合わせて作用さ
せ、試料中のクレアチニン及びクレアチンをホル
ムアルデヒドと過酸化水素とグリシンに変換し、
発生した過酸化水素をカタラーゼ〔EC1.11.1.6〕
の存在下メタノールと反応させてもう1分子のホ
ルムアルデヒドに変換する。これによりクレアチ
ニン及びクレアチン各1分子を各々2分子のホル
ムアルデヒドに変換させることになる。ここに生
じた2倍量のホルムアルデヒドを発色測定するこ
とになるので測定の感度及び精度は非常に高くな
り、クレアチニン及びクレアチンが迅速且つ正確
に測定し得る。
本発明の方法の測定原理を具体的に示せば下記
の通りである。
〔A〕 酵素反応
クレアチニン+H2OCRN
―――→
クレアチン
クレアチン+H2OCR
――→
ザルコシン+尿素
ザルコシン+H2O+O2SOX
―――→
ホルムアルデヒド+グリシン+過酸化水素
過酸化水素+メタノールカタラーゼ
――――――→
ホルムアルデヒド+2H2O
〔B〕 発色反応
2ホルムアルデヒド+発色試薬→発色体 す
なわち試料中のクレアチニンをCRNでクレア
チンに変え、生じたクレアチンをCRでザルコ
シンと尿素に変え、ザルコシンをSOXで過酸
化水素とグリシンに変え、生じた過酸化水素を
カタラーゼでの存在下メタノールと反応させて
ホルムアルデヒドと水に変える酵素反応と、酵
素反応により生じたホルムアルデヒドを発色試
薬と反応させ発色する発色反応とからなり、そ
して生じた発色体の可視部吸光度を測定して、
目的とするクレアチニンを定量することができ
る。上記酵素反応においてCRNを用いないで
酵素反応を進行させるとクレアチンの定量を行
なうことができる。また試料中に存在するクレ
アチニンの量を知りたいときには、上記酵素反
応においてCRNも用いて酵素反応を進行させ
て得たクレアチンとクレアチニンの合計量から
CRNを用いないで酵素反応を進行させて得た
クレアチンの量を差し引くことによつて得られ
る。
本発明に使用するCRNはいかなる起源のもの
でもよいがたとえばアルカリゲネス
(Alcaligenes)属、シユードモナス
(Pseudomonas)属、フラボバクテリウム
(Flavobacterium)属等に属する微生物が産生す
るCRNがある。
本発明に使用するCRはいかなる起源のもので
もよいがたとえばシユードモナス
(Pseudomonas)属、フラボバクテリウム
(Flavobacterium)属、等に属する微生物が産生
するCRがある。
本発明に使用するSOXはいかなる起源のもの
でもよいがたとえばシユードモナス
(Pseudomonas)属、コリネバクテリウム
(Corynebacterium)属、ミクロコツカス
(Micrococcus)属、等に属する微生物が産生す
るSOXがある。
本発明に使用するカタラーゼは動植物、微生物
等いかなる起源のカタラーゼでもよい。
本発明のアルデヒドを定量する発色試薬として
はアルデヒドと反応して定量的に発色するもので
あればいかなるものでもよいが1例として4−ア
ミノ−3−ヒドラジノ−1.2.4−トリアゾール
(以後AHMTと略す)なる化合物がある。この
化合物をアルカリ性下でホルムアルデヒドと反応
させた後、メタ過ヨウ素酸ナトリウムで酸化して
発色させる。
本発明の方法に従つてCRN、CR、SOX及びカ
タラーゼの4酵素を用いてクレアチニン及びクレ
アチンを定量すればヤツフエ反応を用いた方法に
比べ感度よく共存物質の影響を受けずに、特異性
高く正確に体液中のクレアチニン及びクレアチン
の定量が可能であり、臨床検査の診断分野におい
て極めて有意義である。
カタラーゼを用いて過酸化水素をホルムアルデ
ヒドに変換させているため、クレアチニン及びク
レアチン各1分子を各々2分子のホルムアルデヒ
ドに変換したことになり、ここで生じた2倍量の
ホルムアルデヒドを定量しているため、過酸化水
素を発色定量する方法に比べ高感度である。
更に本発明は液中のクレアチニン及びクレアチ
ンを同時定量するキツトを提供するものであり以
下これについて具体的に説明する。
本発明によるクレアチニン及びクレアチンの同
時定量キツトは酵素CRN、CR、SOX、カタラー
ゼの4酵素を含む試薬A、CR、SOX、カタラー
ゼの3酵素を含む試薬B、及びSOX、カタラー
ゼの2酵素を含む試薬Cとホルムアルデヒド発色
試薬とからなる。
キツトにおける試薬A、試薬B及び試薬Cは粉
末状及び液状のいずれの形状でもよく、粉末状の
場合には、酵素CRN、CR、SOX、カタラーゼの
4酵素の酵素作用を行なわしめるに最適なPH6.0
〜9.0を与えるメタノールを含有する緩衝液例え
ば4%メタノールを含有する50mMリン酸緩衝液
(PH7.8)を酵素溶解液として用いる。
また液状の場合は酵素CRN、CR、SOX、カタ
ラーゼ等を含む試薬A、試薬B、及び試薬Cを緩
衝液例えば4%メタノールを含有する50mMリン
酸緩衝液で溶解してPH6.0〜9.0(好ましくはPH7.8)
に調整しておけばよい。
ホルムアルデヒド発色試薬はホルムアルデヒド
を定量的に発色させる試薬であればどのようなも
のでもよいが、1例として3N−水酸化カリウム
溶液、1.0%AHMT溶液、0.04%メタ過ヨウ素酸
ナトリウム溶液等調製したものを挙げることがで
きる。
なおキツトは冷暗所特に5℃以下に保存するこ
とが望ましい。
次に本発明を実施例により説明する。
実施例
試薬中のクレアチニン及びクレアチンを下記試
薬を用い下記方法により定量した。
1 試薬
試薬A
CRN 280単位
CR 360単位
SOX 240単位
カタラーゼ 20000単位
メタノール 0.4ml50
mMリン酸緩衝液(PH7.8) 10ml
試薬B
CR 360単位
SOX 240単位
カタラーゼ 20000単位
メタノール 0.4ml
50mMリン酸緩衝液(PH7.8) 10ml
試薬C
SOX 240単位
カタラーゼ 20000単位
メタノール 0.4ml
50mMリン酸緩衝液(PH7.8) 10ml
試薬D
3N−水酸化カリウム溶液
試薬E
1%AHMT溶液
試薬F
0.04%メタ過ヨウ素酸ナトリウム溶液
2 測定法
試料及びクレアチニン標準液20μをとり、
以後、第1表に示すとうりに操作を行なつて、
波長550nmで吸光後を測定し以下に示す計算
式によつて試料中のクレアチニン及びクレアチ
ン量を求める。
The present invention relates to a method for the simultaneous determination of creatinine and creatine in body fluids, particularly serum or urine, using enzymes, and a kit therefor. Creatine is mainly synthesized in the liver and enters the bloodstream, and most of it is distributed in the muscles, where it is synthesized into creatine phosphate, a high-energy compound, by the action of creatine kinase, and plays an important role as an energy source. Creatine is excreted from the renal glomerulus, but is reabsorbed in the renal tubules, so it is hardly excreted in the urine in adult males.
Serum creatine concentration increases in primary muscle diseases, muscle atrophy, hyperthyroidism, etc., resulting in creatinuria. On the other hand, creatinine, which is an anhydrous form of creatine, is produced in muscle by irreversibly and non-enzymatically dehydrating creatine phosphate, passes through the renal glomerulus as a metabolic end product, and is excreted without being reabsorbed in the renal tubules. Therefore, in the case of renal function diseases such as uremia, chronic nephritis, and urinary tract obstruction, creatinine cannot be excreted normally and creatinine increases in serum. Measuring creatine and creatinine concentrations in serum and urine in this way serves as an important index for the diagnosis of these diseases. The number of specimens continues to increase year by year. The conventionally commonly used method for quantifying creatinine uses the Jacques reaction, which develops color by reacting with picric acid under alkaline conditions (Bonsnes and
Taussky, J. Biol. Chem. 158 581 (1945)). Since this method does not show a specific reaction to creatinine, it is not possible to obtain an accurate amount of creatinine because it is affected by other substances in body fluids, and picric acid may contaminate the reaction vessel or analyzer, causing measurement errors. Become. Furthermore, when adapted to an automatic analyzer, there were many problems in handling, such as affecting other measurement items. On the other hand, creatine is heated in acidic conditions to convert it into creatinine, and the resulting creatinine is measured using the above-mentioned Jacques reaction, and the amount of creatinine is estimated from the difference with the amount of creatinine before acidic heating.For this reason, the creatinine quantitative method eliminates errors. It has the disadvantage that it is easy to occur and the operation is complicated. It has been desired to develop a simple and accurate method for simultaneously quantifying creatinine and creatine that overcomes these conventional drawbacks. Against this background, we conducted extensive research to establish a rapid, highly sensitive, and accurate method for simultaneously quantifying creatinine and creatine.As a result, we developed four enzymes: creatinine amidohydrolase, creatine amidinohydrolase, sarcosine oxidase, and catalase. The inventors have discovered that the intended purpose can be achieved by using a color-forming reagent and have arrived at the present invention.
The present invention converts creatine and creatinine in an aliquot of a sample into formaldehyde, hydrogen peroxide, and glycine by applying a combination of three enzymes: creatinine amidohydrolase, creatine amidinohydrolase, and sarcosine oxidase. , a combination of two enzymes, creatine amidinohydrolase and sarcosine oxidase, was applied to another aliquot of the above sample to convert the creatine in the sample into formaldehyde, hydrogen peroxide and glycine, and the hydrogen peroxide produced in each case 2 per molecule of creatinine and creatine by reacting with methanol in the presence of catalase and converting it to formaldehyde.
Formaldehyde molecules are generated, a coloring reagent is applied to each generated formaldehyde, the resulting chromophore is measured, the total amount of creatinine and creatine, and the amount of creatine are determined, and the amount of creatine is calculated from the total amount. This is a method for simultaneously quantifying creatinine and creatine, which consists of calculating the amount of creatinine by subtracting the amount of creatinine. According to the present invention, the sample contains creatinine amidohydrolase [EC3.5.2.10; hereinafter abbreviated as CRN], creatine amidinohydrolase [EC3.5.3.3; hereinafter abbreviated as CR], and sarcosine oxidase [EC1.5.3.1]. ; hereinafter abbreviated as SOX] are activated in combination to convert creatinine and creatine in the sample into formaldehyde, hydrogen peroxide, and glycine.
Catalase generates hydrogen peroxide [EC1.11.1.6]
It is converted into one more molecule of formaldehyde by reacting with methanol in the presence of . This converts one molecule each of creatinine and creatine into two molecules of formaldehyde. Since twice the amount of formaldehyde generated here is measured by color, the sensitivity and accuracy of the measurement is extremely high, and creatinine and creatine can be measured quickly and accurately. The measurement principle of the method of the present invention is specifically shown below. [A] Enzyme reaction Creatinine + H 2 OCRN ---→ Creatine Creatine + H 2 OCR ---→ Sarcosine + Urea Sarcosine + H 2 O+O 2 SOX ----→ Formaldehyde + Glycine + Hydrogen peroxide Hydrogen peroxide + Methanol catalase --- ―――→ Formaldehyde + 2H 2 O [B] Color reaction 2 Formaldehyde + Color reagent → Chromogen In other words, creatinine in the sample is changed to creatine with CRN, the resulting creatine is changed into sarcosine and urea with CR, and sarcosine is filtered with SOX. An enzymatic reaction that converts hydrogen oxide and glycine into formaldehyde and water by reacting the resulting hydrogen peroxide with methanol in the presence of catalase, and a coloring reaction that develops color by reacting formaldehyde generated by the enzymatic reaction with a coloring reagent. Then, measure the absorbance in the visible region of the resulting colored material,
The target creatinine can be quantified. Creatine can be quantitatively determined by allowing the enzymatic reaction to proceed without using CRN. In addition, when you want to know the amount of creatinine present in a sample, you can use the total amount of creatine and creatinine obtained by advancing the enzyme reaction using CRN in the above enzyme reaction.
It is obtained by subtracting the amount of creatine obtained by proceeding with the enzymatic reaction without using CRN. The CRN used in the present invention may be of any origin, but examples thereof include CRN produced by microorganisms belonging to the genus Alcaligenes, Pseudomonas, Flavobacterium, and the like. The CR used in the present invention may be of any origin, but examples thereof include CR produced by microorganisms belonging to the genus Pseudomonas, the genus Flavobacterium, and the like. The SOX used in the present invention may be of any origin, but examples thereof include SOX produced by microorganisms belonging to the genus Pseudomonas, Corynebacterium, Micrococcus, and the like. The catalase used in the present invention may be of any origin, such as animals, plants, microorganisms, etc. As the coloring reagent for quantifying aldehydes of the present invention, any coloring reagent may be used as long as it reacts with aldehyde and quantitatively develops color. One example is 4-amino-3-hydrazino-1.2.4-triazole (hereinafter referred to as AHMT). There is a compound called (abbreviated). This compound is reacted with formaldehyde under alkaline conditions and then oxidized with sodium metaperiodate to develop color. According to the method of the present invention, quantification of creatinine and creatine using the four enzymes CRN, CR, SOX, and catalase is more sensitive than the method using the Jathue reaction, is not affected by coexisting substances, and is highly specific and accurate. It is possible to quantify creatinine and creatine in body fluids, and it is extremely meaningful in the diagnostic field of clinical tests. Since hydrogen peroxide is converted to formaldehyde using catalase, one molecule each of creatinine and creatine is converted to two molecules of formaldehyde each, and twice the amount of formaldehyde produced here is being quantified. This method is more sensitive than methods that quantify hydrogen peroxide by color. Furthermore, the present invention provides a kit for simultaneously quantifying creatinine and creatine in a liquid, which will be specifically explained below. The kit for simultaneous determination of creatinine and creatine according to the present invention includes a reagent A containing four enzymes: CRN, CR, SOX, and catalase, a reagent B containing three enzymes, CR, SOX, and catalase, and a reagent containing two enzymes, SOX and catalase. C and a formaldehyde coloring reagent. Reagent A, Reagent B, and Reagent C in the kit may be in either powder or liquid form, and in the case of powder, the optimum pH6 for carrying out the enzymatic action of the four enzymes CRN, CR, SOX, and catalase. .0
A buffer containing methanol, such as a 50 mM phosphate buffer (PH 7.8) containing 4% methanol, is used as the enzyme lysing solution. If it is in liquid form, dissolve Reagent A, Reagent B, and Reagent C containing the enzymes CRN, CR, SOX, catalase, etc. in a buffer such as 50mM phosphate buffer containing 4% methanol to a pH of 6.0 to 9.0. preferably PH7.8)
All you have to do is adjust it. Any formaldehyde coloring reagent may be used as long as it is a reagent that quantitatively colors formaldehyde, but examples include 3N potassium hydroxide solution, 1.0% AHMT solution, 0.04% sodium metaperiodate solution, etc. can be mentioned. It is preferable to store the kit in a cool, dark place, especially below 5°C. Next, the present invention will be explained by examples. Example Creatinine and creatine in a reagent were quantified using the following reagent and the following method. 1 Reagent Reagent A CRN 280 units CR 360 units SOX 240 units Catalase 20000 units Methanol 0.4ml50mM phosphate buffer (PH7.8) 10ml Reagent B CR 360 units SOX 240 units Catalase 20000 units Methanol 0.4ml 50mM phosphate buffer (PH7.8) PH7.8) 10ml Reagent C SOX 240 units Catalase 20000 units Methanol 0.4ml 50mM phosphate buffer (PH7.8) 10ml Reagent D 3N-Potassium hydroxide solution Reagent E 1% AHMT solution Reagent F 0.04% Sodium metaperiodate Solution 2 Measurement method Take 20μ of the sample and creatinine standard solution,
Thereafter, perform the operations as shown in Table 1,
After absorbing light at a wavelength of 550 nm, measure the amount of creatinine and creatine in the sample using the formula shown below.
【表】【table】
【表】
クレアチニンの検量線を第1図、クレアチン
の検量線を第2図に示す。
また管理血清を試料とした場合のクレアチニ
ンの測定値は第2表の通りであつた。[Table] The calibration curve for creatinine is shown in Figure 1, and the calibration curve for creatine is shown in Figure 2. Furthermore, the measured values of creatinine when control serum was used as a sample were as shown in Table 2.
【表】
上記試薬を用いて血清中のクレアチニン濃度
を求め従来のヤツフエ反応法と比較した。その
結果は第3表の通りであつた。[Table] Using the above reagent, the concentration of creatinine in serum was determined and compared with the conventional Jacques reaction method. The results were as shown in Table 3.
【表】【table】
【表】
なおヤツフエ反応法は試料にピクリン酸およ
び水酸化ナトリウムの溶液を加え、活性メチレ
ンの反応により生じた紅色の化合物の吸光度を
測定する。標準液を同様にして操作して515n
mで比色し、試料中の濃度を求める方法であ
る。本発明方法は従来のヤツフエ法と比較して
特異的な酵素反応を用いるものであり正確な測
定を行なうことができ、また試料中のクレアチ
ニンとクレアチンを同時に定量できる。
以上詳細に説明した如く、本発明は液中のクレ
アチニン及びクレアチンを正確かつ迅速に同時定
量する方法及びそのキツトを提供するものであつ
て特に臨床医学における腎臓及び筋疾患の診断に
有効に用いることができるものである。[Table] In the Yatsufue reaction method, a solution of picric acid and sodium hydroxide is added to a sample, and the absorbance of the red compound produced by the reaction of active methylene is measured. The standard solution was operated in the same way to 515n.
This method calculates the concentration in the sample by comparing the colors with m. The method of the present invention uses a specific enzymatic reaction compared to the conventional Yatsufue method and can perform accurate measurements, and can simultaneously quantify creatinine and creatine in a sample. As explained in detail above, the present invention provides a method and a kit for simultaneously quantifying creatinine and creatine in a liquid accurately and rapidly, and is particularly useful for diagnosing kidney and muscle diseases in clinical medicine. It is something that can be done.
第1図はクレアチニンの検量線であり、第2図
はクレアチンの検量線である。
FIG. 1 is a calibration curve for creatinine, and FIG. 2 is a calibration curve for creatine.
Claims (1)
ミドヒドロラーゼ、クレアチン・アミジノヒドロ
ラーゼ、ザルコシン・オキシダーゼの3酵素を組
合せて作用させて該試料中のクレアチンとクレア
チニンをホルムアルデヒド、過酸化水素及びグリ
シンに変換し、上記試料の他のアリコートにクレ
アチン・アミジノヒドラーゼとザルコシン・オキ
シダーゼの2酵素を組合せて作用させて試料中の
クレアチンをホルムアルデヒド、過酸化水素及び
グリシンに変換し、各々の場合に生じた過酸化水
素をカタラーゼの存在下にメタノールと反応させ
てホルムアルデヒドに変換させることによりクレ
アチニン及びクレアチン各1分子当り2分子のホ
ルムアルデヒドを生成させ、各々生じたホルムア
ルデヒドに発色試薬を作用させ、生じた発色体を
測定して各々クレアチニンとクレアチンの合計量
及びクレアチンの量を定量し、該合計量からクレ
アチンの量を差引くことによりクレアチニンの量
を算出することからなるクレアチニンとクレアチ
ンの同時定量方法。 2 発色試薬が3N−水酸化カリウム溶液、1%
4−アミノ−3−ヒドラジノ−1,2,4−トリ
アゾール溶液および0.04%メタ過ヨウ素酸ナトリ
ウム溶液である特許請求の範囲第1項記載の方
法。 3 クレアチニン・アミドヒドロラーゼ、クレア
チン・アミジノヒドロラーゼ、ザルコシン・オキ
シダーゼ及びカタラーゼの4酵素を含む試薬A;
クレアチン・アミジノヒドロラーゼ、ザルコシ
ン・オキシダーゼ及びカタラーゼの3酵素を含む
試薬B;ザルコシン・オキシダーゼ及びカタラー
ゼの2酵素を含む試薬C及びホルムアルデヒド発
色試薬からなるクレアチニンとクレアチンの同時
定量用キツト。 4 発色試薬が3N−水酸化カリウム溶液、1%
4−アミノ−3−ヒドラジノ−1,2,4−トリ
アゾール溶液および0.04%メタ過ヨウ素酸ナトリ
ウム溶液である特許請求の範囲第3項記載のキツ
ト。[Claims] 1. A combination of three enzymes, creatinine amidohydrolase, creatine amidinohydrolase, and sarcosine oxidase, is applied to one aliquot of a sample to convert creatine and creatinine in the sample into formaldehyde, hydrogen peroxide, and glycine. creatine amidinohydrase and sarcosine oxidase are applied to another aliquot of the above sample in combination to convert the creatine in the sample into formaldehyde, hydrogen peroxide and glycine, producing in each case Hydrogen peroxide is reacted with methanol in the presence of catalase to convert it into formaldehyde, producing two molecules of formaldehyde for each molecule of creatinine and creatine, and a coloring reagent is applied to each of the resulting formaldehyde to produce the resulting color. A method for simultaneously quantifying creatinine and creatine, which comprises measuring the body, determining the total amount of creatinine and creatine, and calculating the amount of creatinine by subtracting the amount of creatine from the total amount. 2 Coloring reagent is 3N potassium hydroxide solution, 1%
The method of claim 1, wherein the 4-amino-3-hydrazino-1,2,4-triazole solution and the 0.04% sodium metaperiodate solution. 3 Reagent A containing four enzymes: creatinine amidohydrolase, creatine amidinohydrolase, sarcosine oxidase, and catalase;
A kit for the simultaneous determination of creatinine and creatine, consisting of Reagent B containing three enzymes, creatine amidinohydrolase, sarcosine oxidase, and catalase; Reagent C containing two enzymes, sarcosine oxidase and catalase; and a formaldehyde coloring reagent. 4 Coloring reagent is 3N potassium hydroxide solution, 1%
The kit according to claim 3, which is a 4-amino-3-hydrazino-1,2,4-triazole solution and a 0.04% sodium metaperiodate solution.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP24790483A JPS60135865A (en) | 1983-12-26 | 1983-12-26 | Method and kit for simultaneous quantitative analysis of creatinine and creatine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP24790483A JPS60135865A (en) | 1983-12-26 | 1983-12-26 | Method and kit for simultaneous quantitative analysis of creatinine and creatine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS60135865A JPS60135865A (en) | 1985-07-19 |
| JPH0380480B2 true JPH0380480B2 (en) | 1991-12-25 |
Family
ID=17170285
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP24790483A Granted JPS60135865A (en) | 1983-12-26 | 1983-12-26 | Method and kit for simultaneous quantitative analysis of creatinine and creatine |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS60135865A (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105555962A (en) * | 2013-10-04 | 2016-05-04 | Csquare株式会社 | Test strip using formaldehyde or peroxide, from among sarcosine metabolites, for diagnosing prostate cancer, and method for diagnosing prostate cancer using same |
-
1983
- 1983-12-26 JP JP24790483A patent/JPS60135865A/en active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPS60135865A (en) | 1985-07-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Spencer | Analytical reviews in clinical biochemistry: the estimation of creatinine | |
| US3950226A (en) | Novel reagent and method for the determination of urea in biological fluids | |
| Orsonneau et al. | Simple and sensitive determination of urea in serum and urine | |
| JPS59193352A (en) | Reagent for analysis, method of analysis and element of multiple chemical analysis | |
| DK151974B (en) | PROCEDURE AND REAGENT USE OF THIS, IN DETERMINING GLUTAMATE OXALACETATE TRANSAMINASE AND GLUTAMATE PYRUVATE TRANSAMINASE | |
| JPS59183698A (en) | Quantitative determination of substrate | |
| JPH0380480B2 (en) | ||
| US3649198A (en) | Diagnostic method for the determination of uric acid in blood | |
| Okamura | A specific method for determination of total ascorbic acids in urine by the α, α-dipyridyl method | |
| IL46338A (en) | Determination of serum creatinne | |
| JPS603480B2 (en) | Creatinine and creatine determination method | |
| US5888828A (en) | Kit for measuring urea nitrogen | |
| JPS61155758A (en) | Simultaneous assay of creatinine and creatine and kit therefor | |
| US4096037A (en) | Arginase test | |
| Hashim et al. | Wet vs. dry chemical analysis of renal stones | |
| Rindfrey et al. | Kinetic determination of glucose concentrations with glucose dehydrogenase | |
| SuzuKI | Determination of total bilirubin in serum by a color reaction using p-dimethylaminobenzaldehyde | |
| NO803552L (en) | DIAGNOSTIC SAMPLES FOR URINE. | |
| JPH04271799A (en) | Method for measuring creatinine by enzyme and its reagent | |
| JP2761768B2 (en) | Method for determining NADH and method for determining bile acid using the same | |
| JPS6030696A (en) | Method and reagent for determination of creatinine and creatine | |
| US4727025A (en) | Process and reagent for the fully enzymatic determination of urea | |
| JPH0731498A (en) | Determination kit for 1,5-anhydroglucitol and determination method using the kit | |
| JPH04252197A (en) | Assay method for catechol and its product and factor thereof | |
| WO1994023061A1 (en) | Method of determining sodium ion |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| LAPS | Cancellation because of no payment of annual fees |